<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05096858</url>
  </required_header>
  <id_info>
    <org_study_id>3066</org_study_id>
    <nct_id>NCT05096858</nct_id>
  </id_info>
  <brief_title>Continuous Glucose Monitorization in Hospitalized Patients With COVID-19</brief_title>
  <official_title>Assessment of the Effect of Continuous Glucose Monitorization on Glycemic Variability and Insulin's Prescription in Hospitalized Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      DM2 is a major comorbidity of COVID-19. It has been observed that subjects with DM2 require&#xD;
      more medical interventions, have a significantly higher mortality (7.8% versus 2.7%) and&#xD;
      injuries of multiple organs that the individuals not diabetics.&#xD;
&#xD;
      In situations of glycemic variability, phenomena of oxidative stress and activation of&#xD;
      protein kinase C can be initiated , through the release of pro-inflammatory cytosines , which&#xD;
      could induce microvascular damage .Patients with diabetes and COVID-19 were shown to be more&#xD;
      likely to develop serious or critical illness with more complications, and to have higher&#xD;
      incidence rates of antibiotic therapy, non-invasive and invasive mechanical ventilation, and&#xD;
      death (11.1% vs. 4.1%).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose variability</measure>
    <time_frame>For up to two weeks, during hospitalization</time_frame>
    <description>Percentage of time within the ADA recommended range</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin use</measure>
    <time_frame>For up two weeks, during hospitalization</time_frame>
    <description>Average daily UI of insulin per patient</description>
  </primary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Covid19</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adults living with diabetes and suffering from COVID19 pneumonia&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed COVID-19 pneumonia&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Less than 3 days of hospital care&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ALFONSO GULIAS HERRERO</last_name>
    <role>Principal Investigator</role>
    <affiliation>INCMNSZ</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ALFONSO GULIAS HERRERO</last_name>
    <phone>523123173679</phone>
    <email>alfonso.guliash@incmnsz.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ALHELY GAYTAN SANTILLAN</last_name>
    <email>alhely.gaytans@incmnsz.mx</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Institute of Medical Sciences and Nutrition Salvador Zubiran</name>
      <address>
        <city>Mexico City</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alhely Gaytan Santillan</last_name>
      <phone>523123173679</phone>
      <email>alhely.gaytans@incmnsz.mx</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 13, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

